Drug Profile
Research programme: Pan-HER inhibitors - SUGEN/Baxter Oncology
Alternative Names: D-69491; SU 11464Latest Information Update: 11 Dec 2002
Price :
$50
*
At a glance
- Originator ASTA Medica [CEASED]; SUGEN
- Developer Baxter Oncology; SUGEN
- Class Small molecules
- Mechanism of Action Epidermal growth factor inhibitors; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Dec 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn